A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Recruiting

Phase 3

Pembrolizumab & Sacituzumab GovitecanA Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06524544

Conditions

Locally Advanced Urothelial Carcinoma

Metastatic Urothelial Carcinoma

Unresectable Urothelial Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Carboplatin

Cisplatin

Computed Tomography

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-26. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-05-22.